Literature DB >> 24694397

Evaluation of a mouse model for the West Nile virus group for the purpose of determining viral pathotypes.

John Bingham1, Jean Payne1, Jennifer Harper1, Leah Frazer1, Sarah Eastwood1, Susanne Wilson1, Sue Lowther1, Ross Lunt1, Simone Warner2, Mary Carr3, Roy A Hall4, Peter A Durr1.   

Abstract

West Nile virus (WNV; family Flaviviridae; genus Flavivirus) group members are an important cause of viral meningoencephalitis in some areas of the world. They exhibit marked variation in pathogenicity, with some viral lineages (such as those from North America) causing high prevalence of severe neurological disease, whilst others (such as Australian Kunjin virus) rarely cause disease. The aim of this study was to characterize WNV disease in a mouse model and to elucidate the pathogenetic features that distinguish disease variation. Tenfold dilutions of five WNV strains (New York 1999, MRM16 and three horse isolates of WNV-Kunjin: Boort and two isolates from the 2011 Australian outbreak) were inoculated into mice by the intraperitoneal route. All isolates induced meningoencephalitis in different proportions of infected mice. WNVNY99 was the most pathogenic, the three horse isolates were of intermediate pathogenicity and WNVKUNV-MRM16 was the least, causing mostly asymptomatic disease with seroconversion. Infectivity, but not pathogenicity, was related to challenge dose. Using cluster analysis of the recorded clinical signs, histopathological lesions and antigen distribution scores, the cases could be classified into groups corresponding to disease severity. Metrics that were important in determining pathotype included neurological signs (paralysis and seizures), meningoencephalitis, brain antigen scores and replication in extra-neural tissues. Whereas all mice infected with WNVNY99 had extra-neural antigen, those infected with the WNV-Kunjin viruses only occasionally had antigen outside the nervous system. We conclude that the mouse model could be a useful tool for the assessment of pathotype for WNVs.
© 2014 CSIRO.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694397     DOI: 10.1099/vir.0.063537-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Virulence and Evolution of West Nile Virus, Australia, 1960-2012.

Authors:  Natalie A Prow; Judith H Edmonds; David T Williams; Yin X Setoh; Helle Bielefeldt-Ohmann; Willy W Suen; Jody Hobson-Peters; Andrew F van den Hurk; Alyssa T Pyke; Sonja Hall-Mendelin; Judith A Northill; Cheryl A Johansen; David Warrilow; Jianning Wang; Peter D Kirkland; Stephen Doggett; Christy C Andrade; Aaron C Brault; Alexander A Khromykh; Roy A Hall
Journal:  Emerg Infect Dis       Date:  2016-08       Impact factor: 6.883

2.  STING is required for host defense against neuropathological West Nile virus infection.

Authors:  Kathryn McGuckin Wuertz; Piper M Treuting; Emily A Hemann; Katharina Esser-Nobis; Annelise G Snyder; Jessica B Graham; Brian P Daniels; Courtney Wilkins; Jessica M Snyder; Kathleen M Voss; Andrew Oberst; Jennifer Lund; Michael Gale
Journal:  PLoS Pathog       Date:  2019-08-15       Impact factor: 6.823

3.  Spinal Cord Ventral Horns and Lymphoid Organ Involvement in Powassan Virus Infection in a Mouse Model.

Authors:  Rodrigo I Santos; Meghan E Hermance; Benjamin B Gelman; Saravanan Thangamani
Journal:  Viruses       Date:  2016-08-12       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.